Roche, BC Cancer & CPHIN collaborate to generate real-world evidence
- This collaboration, called Precision Oncology Evidence Development in Cancer Treatment, or PREDiCT, aims to generate and assess real-world evidence, and with this data influence the development of new reimbursement pathways for precision oncology therapies
- Biomarker-informed precision oncology drugs are often indicated for rare subpopulations of cancer patients, making traditional analyses difficult – PREDiCT will encourage greater use of real-world evidence in regulatory and reimbursement decisions
Click here to learn more.
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.